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A range of medications target different aspects of the GABA system; understanding their effects is
important to inform further drug development. Effects on the waking EEG comparing these mechanisms
have not been reported; in this study we compare the effects on resting MEG spectra of the benzodi-
azepine receptor agonist zolpidem, the delta sub-unit selective agonist gaboxadol (also known as THIP)
and the GABA reuptake inhibitor tiagabine. These were two randomised, single-blind, placebo-
controlled, crossover studies in healthy volunteers, one using zolpidem 10 mg, gaboxadol 15 mg and
placebo, and the other tiagabine 15 mg and placebo. Whole head MEG recordings and individual MEG
spectra were divided into frequency bands. Baseline spectra were subtracted from each post-intervention
spectra and then differences between intervention and placebo compared. After zolpidem there were
signiﬁcant increases in beta frequencies and reduction in alpha frequency power; after gaboxadol and
tiagabine there were signiﬁcant increases in power at all frequencies up to beta. Enhancement of tonic
inhibition via extrasynaptic receptors by gaboxadol gives rise to a very different MEG signature from the
synaptic action of zolpidem. Tiagabine theoretically can affect both types of receptor; from these MEG
results it is likely that the latter is the more prominent effect here.
This article is part of the Special Issue entitled ‘GABAergic Signaling in Health and Disease’.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction and rationale
The GABA system is the key inhibitory system in the brain and
many neuropsychiatric disorders result from its dysregulation
including insomnia, epilepsy, anxiety disorders, some aspects of
substance abuse and possibly psychosis. There are a range of
medications that target different aspects of this system and un-
derstanding their effects is important to inform further drug
development. One approach has been to examine the effects of
medication on EEG-measured sleep architecture in humans. These
studies have shown marked differences between the drugs which
promote GABA function by effects on extrasynaptic receptors [e.g.armacology, Division of Brain
rlington Danes Building, Du
7047.
Ltd. This is an open access article ugaboxadol ], or by inhibition of reuptake [e.g. tiagabine], compared
with the positive allosteric modulators (PAMs) such as the benzo-
diazepines. Therefore it would be interesting to look at the effects
of these different classes of drugs on the waking state to compare
brain mechanisms.
In this paper we report on the use of humanMEG to examine the
actions of 3 drugs acting on this system e speciﬁcally the intra-
synaptic benzodiazepine alpha-1 selective receptor site PAM zol-
pidem, the extra-synaptic alpha-4 delta receptor PAM gaboxadol
and a presumed synaptic GAT1 GABA reuptake blocker tiagabine,
all of which have been used for the treatment of human brain
disorders.
GABA-A benzodiazepine receptor PAMs such as benzodiaze-
pines and zolpidem enhance synaptic phasic inhibitory currents.
Their effects on EEG have been studied extensively in man. During
waking, and persisting into sleep, they give rise to a dose-
dependent and plasma-concentration-dependent appearance of a
regular, smoothly formed beta rhythm over the whole of thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
D. Nutt et al. / Neuropharmacology 88 (2015) 155e163156cortical region, beginning at the frontal area (Greenblatt et al.,
2006; Malizia et al., 1996). This rhythmic beta activity has no cor-
relation with state of awareness but is correlated with brain
benzodiazepine receptor occupation (Malizia et al., 1996). It is seen
in the EEG healthy participants receiving acute doses of these drugs
for research studies, but also in patients who are taking the drugs
long-term and are tolerant to their sedative effects. Barbiturates
also produce this beta activity, and both they and benzodiazepines
have been used clinically for many years to identify areas of
damaged cortex in epilepsy and other disorders: the so-called ‘beta
gap’ where damaged tissue does not produce this drug-induced
rhythm (Claus et al., 2012, 2009; Pampiglione, 1952). A MEG
study of diazepam described increased power and decreased fre-
quency of beta oscillations over rolandic areas and attributed this to
an increase in IPSCs onto inhibitory neurons rather than an increase
in IPSCs onto excitatory pyramidal cells (Jensen et al., 2005). These
drugs also reduce alpha-frequency activity over the whole cortical
area (Connemann et al., 2005) during wakefulness. During sleep,
there are the usual EEG signs of reduced awareness with increases
in slower activity as in normal drowsiness and sleep, but these PAM
drugs increase the amount of spindle activity, and in higher doses
reduce delta activity (Brunner et al., 1991; Hindmarch et al., 2005;
Karacan et al., 1981).
Gaboxadol also known as THIP (4,5,6,7-tetrahydroisox
azolopyridin-3-ol) is the ﬁrst extra-synaptic GABA-A agonist to
have been used in humans (Faulhaber et al., 1997). It enhances tonic
GABA-A-mediated current (Drasbek et al., 2007) and has sleepFig. 1. Summary of total scores (upper panels) for participants on the subjective high asses
item (sleepy) displayed on the lower charts. The SHAS consists of 13 items scored 0e100. Th
“nauseated”, “drunk”, “sleepy”, “distorted sense of time”, “effects of alcohol”, “difﬁculty conpromoting properties (Lancel et al., 2001) but can cause undesir-
able mental effects at higher doses. There are no published studies
of the effect of gaboxadol on EEG or subjective ratings during
wakefulness in man. In mice, both waking and sleeping EEG show a
dramatic increase in slower EEG frequencies (<6 Hz) after gabox-
adol, and this effect is not seen in mice deﬁcient in the GABA-A
delta-subunit gene (Winsky-Sommerer et al., 2007). Human sleep
studies have described gaboxadol's effects in detail, with reports of
marked increases in power in frequencies below 10 Hz delta and
high theta activity and reduction of sleep spindles (Dijk et al., 2010;
Walsh et al., 2007). There are no reported studies of MEG and
gaboxadol.
Tiagabine is a GAT1 reuptake blocker originally developed as a
treatment for epilepsy, whose effects are largely thought to be on
intra-synaptic GABA (Madsen et al., 2009). The extent of GABA
spillover into peri- and extra-synaptic space after GAT1 blockade is
not well understood, but may contribute to tiagabine's effects.
Extra-synaptic and pre-synaptic GABA mechanisms such as tonic
inhibition and feedback autoinhibition may be activated by reup-
take blockade (Axmacher and Draguhn, 2004). The effect of tiaga-
bine on waking EEG in man has not been reported, although there
are MEG studies of stimulus-related responses after tiagabine
(Muthukumaraswamy et al., 2012, 2013b). In the rat in the awake
state there was a small increase in beta band power in one study
(Cleton et al., 1999) and no signiﬁcant change in any spectral band
in another (Lancel et al., 1998). Its effect on the human EEG has been
studied during sleep (Mathias et al., 2001; Walsh et al., 2006); insment scale for gaboxadol/zolpidem (left) and tiagabine (right) with a single sub-scale
ese items are “uncomfortable”, “high”, “clumsy”, “muddled”, “slurred speech”, “dizzy”,
centrating” and “feeling of ﬂoating”.
Fig. 2. Summary of scores for participants on the biphasic alcohol effects scale for gaboxadol/zolpidem (left) and tiagabine (right). The upper panels represent summed negative
effects whereas the lower panels represent positive effects. Scale-items contributing to the negative effects include “difﬁculty in concentrating”, “down”, “heavy head”, “inactive”,
“sedated”, “slow thoughts” and “sluggish”. Scale-items contributing to the positive effects include “elated”, “energised”, “excited” “stimulated” “talkative”, “up” and “vigorous”.
Items are scored between 0 and 8.
D. Nutt et al. / Neuropharmacology 88 (2015) 155e163 157non-REM sleep it gave rise to a marked increase in power in all
frequencies below 10 Hz and in REM sleep this increase was more
prominent for frequencies between 5 and 10 Hz.
Magnetoencephalography (MEG) is a neuroimaging technique
with high temporal resolution and moderately good spatial reso-
lution that allows direct measurement of the magnetic ﬁelds
generated by synchronised ionic neural currents in the brain.When
combined with pharmacological interventions, MEG (pharmaco-
MEG) is a powerful tool for measuring the effects of experimental
modulations of neurotransmission in the living human brain, in
both patient and healthy control groups (Muthukumaraswamy,
2014). Compared with EEG, it provides superior spatial resolution,
and reduced contamination of the brain signals by physiological
artefacts such as blinks and muscle potentials.
In this study we examined resting MEG spectra to investigate
the impact of three GABAergic drugs with highly speciﬁc and
distinct mechanisms of action. We studied the effect of zolpidem
and gaboxadol on resting MEG and compared with previously
collected but not reported resting data from a previous study of
tiagabine, using a similar protocol (Muthukumaraswamy et al.,
2012).
2. Methods
2.1. Design and participants
These were two randomised, single-blind, placebo-controlled, crossover studies
in healthy volunteers. One was a comparison of single doses of zolpidem, gaboxadoland placebo, and the other a comparison of tiagabine with placebo. We chose doses
of 15 mg gaboxadol and 10 mg zolpidem which were well-tolerated and approxi-
mately equipotent with regard to sleep parameters in a study of insomnia (Hajak
et al., 2009). The elimination half-lives of these two drugs is similar at approxi-
mately 1.5e2.0 h in fasting subjects. The 15 mg dose of tiagabine study was chosen
because it could be administered as standard tablet doses, is very similar to the
16 mg used in a PET study by Frankle et al. (2012) and is identical with that used in
several ongoing imaging studies by our group (Muthukumaraswamy et al., 2013b;
Stokes et al., 2014) which have shown that GABA levels are increased.
Both studies were conducted at Cardiff University Brain Research Imaging
Centre with similar protocols, and were approved by the UK National Research
Ethics Service and local NHS Trust research authorities.
Twelve healthy male participants (mean age 27.7, range 21e35) took part in the
zolpidem/gaboxadol experiment. We were unable to collect gaboxadol data from 2
of these. (Participants for the tiagabine experiment were the same as those for
which we have previously published task-related data (Muthukumaraswamy et al.,
2013b)). These included fourteen healthy males and one healthy female participant
(mean age 25.5, range 20e32). In this experiment we had originally intended to use
a mixed sex cohort, however early in data collection we found that all but one fe-
males became too heavily sedated to complete the protocol; therefore females were
subsequently excluded during data collection (see Hamandi et al., 2014 for further
elaboration). All participants were medically screened and excluded for signiﬁcant
medical, psychiatric or neurological condition and current recreational or pre-
scription drug use. They were tested before each session for drugs of abuse (urine
screen) and breath alcohol.
For each session, participants were scanned on separate days, after at least a
seven day washout period, at approximately the same time-of-day. On each day,
an initial baseline MEG recording was obtained. Participants then orally ingested
a capsule containing either placebo/15 mg of tiagabine (tiagabine experiment) or
placebo/15 mg of gaboxadol/10 mg of zolpidem (zolpidem/gaboxadol experi-
ment). Participants were blinded to the contents of the capsules and placebo/
control session order was counterbalanced across both experiments. For the
Fig. 3. Statistical analysis of planar gradiometer conﬁgured MEG data for the zolpidem
experiment (n ¼ 12). “Pre” recordings were subtracted from each time-point and then
a contrast performed between zolpidem and placebo. Red indicates relatively more
power following the drug and blue indicates relatively less. Units are t statistics. Sig-
niﬁcant sensor clusters are marked such that dark circles correspond to p  01, and
crosses to p < 0.05. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
Fig. 4. Statistical analysis of planar gradiometer conﬁgured MEG data for the gabox-
adol experiment (n ¼ 10). “Pre” recordings were subtracted from each time-point and
then a contrast performed between gaboxadol and placebo. See Fig. 3 for further
details.
D. Nutt et al. / Neuropharmacology 88 (2015) 155e163158tiagabine experiment, following drug administration, MEG recordings were ob-
tained from the participants at 60, 180 and 300 min time-points. For the
gaboxadol/zolpidem experiment MEG recordings were obtained at 60 and
160 min time-points. At the conclusion of every MEG recording, the participants
completed subjective questionnaires focussing on the expected effects of GABA-
ergic drugs. These were the Subjective High Assessment Scale (Schuckit, 1980)
which presents 13 items (see Fig 1 and legend) and asks subjects to mark a visual
analogue line anywhere from 0 to 10 cm, and the Biphasic Alcohol Effects Scale
(Martin et al., 1993), which presents 7 items related to sedation and 7 related to
stimulation effects (see Fig 2 and legend) and asks the subject to rate each of
these effects on a 9 point scale. They were also asked to qualitatively report their
psychological state.During each MEG session, 5 min resting recordings were obtained. In the tia-
gabine experiment participants sat with their eyes closed while in the gaboxadol/
zolpidem experiment participants had their eyes open.
Zolpidem and tiagabine were sourced from an NHS hospital pharmacy, and
gaboxadol was donated by Lundbeck as part of the ECNP Medicines Chest Initiative
(Nutt et al., 2014).
2.2. MEG acquisition and analysis
Whole head MEG recordings were made using a CTF 275-channel radial gradi-
ometer system sampled at 1200 Hz (0e300 Hz bandpass). An additional 29 refer-
ence channels were recorded for noise cancellation purposes and the primary
sensors were analysed as synthetic third-order gradiometers (Vrba and Robinson,
2001). Three of the 275 channels were turned off due to excessive sensor noise.
For analysis, the 5 min of resting data were high-pass ﬁltered at 1 Hz, and
segmented into epochs of 2 s in length. Hence, there were 150 epochs available for
analysis. Each epoch was ﬁrst visually inspected, and those with gross artefacts (e.g.,
head movements, jaw clenches) were removed from the analysis. Of the 222 MEG
Fig. 5. Statistical comparison of zolpidem data at 60 min with gaboxadol data at
160 min (n ¼ 10) for planar gradiometer conﬁgured MEG data. See Fig. 3 for further
details.
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(std 5.77; range 0e41%). For the gaboxadol/zolpidem experiment we applied in-
dependent components analysis, as implemented in EEGLAB (Delorme and Makeig,
2004), to the data, to identify and remove low-frequency artefact components
related to eye-blinks and eye-movements. Using the FieldTrip toolbox (Oostenveld
et al., 2011), we converted our MEG data to planar gradient conﬁguration and
then conducted a frequency analysis of the individual vector directions. Frequency
analysis was conducted using Hanning windowed fast Fourier transforms between 1
and 100 Hz at 0.5 Hz frequency steps and then the planar directions combined to
give local maximal under the sensors. Analysis of sensor-level MEG data in a planar
gradient (spatial-derivative) conﬁguration has the advantage of easy interpretability
as ﬁeldmaps can be interpreted as having a source directly underneath ﬁeldmaxima
(Bastiaansen and Knosche, 2000).
For statistical analysis we divided individual spectra into the following fre-
quency bands, delta (1e4 Hz), theta (4e8 Hz), alpha (8e13 Hz), beta (13e30 Hz), low
gamma (30e50 Hz) and high gamma (50e100 Hz) (Muthukumaraswamy et al.,
2013a). The pre-intervention baseline spectra were subtracted from each post-
intervention spectra and then differences between intervention and placebo
tested using permutation testing of t statistics at each post intervention time-point
(Nichols and Holmes, 2002; Maris and Oostenveld, 2007). The type 1 error rate was
controlled using cluster randomization analysis with an initial cluster forming
threshold of p ¼ 0.05 repeated over 500 permutations. To perform correlations with
psychometric measures a similar approach was used where we correlated the
sensor-level power on each recording with various psychometric measures using
the same randomisation approach.
3. Results
The SHAS total scores for zolpidemwere signiﬁcantly elevated at
the 60 (t ¼ 4.39, p ¼ 0.0011) but not at the 160 min time points
(t¼ 1.33 p¼ 0.2; see Fig. 1). SHAS scores were signiﬁcantly elevated
for gaboxadol at both the 65 (t ¼ 3.17 p ¼ 0.201) and 160 (t ¼ 2.50
p ¼ 0.034) minute time-points. For tiagabine, SHAS scores were
signiﬁcantly elevated at the 60 (t ¼ 6.00 p ¼ 3.2e-05), 180 (t ¼ 6.48
p¼ 1.4e-05) and 300 (t¼ 2.4 p¼ 0.028) minute time-points. For the
item “sleepy”, neither zolpidem nor gaboxadol were signiﬁcantly
different to placebo at either time-point, but as can be seen from Fig
1, the highest mean score for sleepiness was at 60 min for zolpidem
and 160 min for gaboxadol. All subjective ratings returned to
baseline levels in the assessment at 240 min (data not shown).
However, for tiagabine this item was elevated at the 60 (t ¼ 3.0
p ¼ 0.01) and 180 (t ¼ 8.6 p ¼ 5.7e-07) minute time-points but not
at 300 min (t ¼ 1.3 p ¼ 0.21).In Fig. 2 the results of BAES scores are plotted, sub-divided into
total sedating and stimulating effects. Neither gaboxadol nor zol-
pidem showed signiﬁcantly different sedating effects at the 60 or
160 min time-points. Conversely, tiagabine showed elevated
sedation effects at 60 (t¼ 5.02 p¼ 1.9e-04), 120 (t¼ 5.6 p¼ 1.1e-05)
and 180 (t ¼ 4.1 p ¼ 0.001) minute time-points. For stimulatory
effects, zolpidem showed enhanced effects at 60 (t ¼ 6.67 p ¼ 5.6e-
05) minutes but not at 160 min while gaboxadol showed enhanced
effects at 60 (t ¼ 2.68 p¼ 0.02) and 165 (t¼ 2.68 p¼ 0.03) minutes.
Tiagabine showed no stimulatory effects.
Zolpidem showed signiﬁcantly enhanced delta power (1e4 Hz)
at both time-points, but reduced alpha power (8e13 Hz; see Fig. 3).
Additionally, at 60 min there was signiﬁcantly enhanced beta and
low gamma. For gaboxadol, there was a general enhancement of
low frequency power from the delta through beta range (1e30 Hz;
see Fig. 4). Direct comparison of the peak effects of gaboxadol and
zolpidem at peak (60 min for zolpidem and 160 min for gaboxadol)
revealed that gaboxadol showed signiﬁcantly enhanced delta, theta
and alpha activity, with the increases in delta power having a more
anterior focus. Similar to gaboxadol, for tiagabine there was
enhancement of low frequency power through the delta through
beta range. This enhancement was spatially widespread in the delta
and theta frequency ranges while in the alpha and beta bands
posterior occipital/parietal increases were absent and slightly
(although non-signiﬁcantly) reversed. Additionally for tiagabine, at
the 180 min time-point there was a decrease in both low
(30e50 Hz) and high frequency (50e100 Hz) gamma power cen-
tred over parietal sensors (see Fig. 5). Since our cohort included
only one female we performed a subsidiary analysis with this
participant excluded( see Supplementary materials) with nearly
identical results seen. The peak time points of drug effect for each
drug are plotted side-by side, to facilitate qualitative comparison of
the spectral effects of the three drugs (See Fig. 7).
Finally, the exploratory correlational analysis of the four psy-
chometric variables shown in Figs. 1 and 2 with the unsubtracted
MEG time-point data analysed in Fig. 6 revealed no meaningful
patterns of correlations.
4. Discussion
In this study we qualitatively evaluated the effects of three
GABAergic modulators, with very different sites of action; gabox-
adol, an extra-synaptic GABA-A PAM, zolpidem, an intra-synaptic
GABA-A PAM and tiagabine, a reuptake inhibitor on whole-head
MEG spectra. Gaboxadol and tiagabine were most similar in
increasing low frequency rhythms from delta through to beta
whereas zolpidem increased delta and beta but decreased theta
and alpha. All three drugs tended to reduce parietal high frequency
gamma rhythms, most notably tiagabine. We expected both
gaboxadol and zolpidem to produce sedation as a result of their
mechanism to enhance GABA action, and this was indeed the case.
However although the absorption characteristics and elimination
half-lives of zolpidem and gaboxadol are reported to be similar, we
noted from both MEG and subjective measurement of sleepiness
that effects of zolpidem were earlier to appear and diminish than
those of gaboxadol. Correlations between subjective and objective
results did not reveal any meaningful associations, but it is noto-
riously difﬁcult to derive signiﬁcant results from these e the way
each individual assesses themselves on subjective scales differs
widely.
The impact of zolpidem on MEG in our study is consistent with
those previously reported in EEG studies, with increase in beta
frequencies and reduction in alpha frequency power. In addition,
we can now report from the current MEG study that it also in-
creases low gamma power, a frequency that is not possible to assess
Fig. 6. Statistical analysis of planar gradiometer conﬁgured MEG data for the tiagabine experiment (n ¼ 10). “Pre” recordings were subtracted from each time-point and then a
contrast performed between tiagabine and placebo. See Fig. 3 for further details.
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the other 2 drugs.
We report here for the ﬁrst time the impact of gaboxadol and
tiagabine on resting MEG. Importantly, there was very little simi-
larity to zolpidem, with increases in power at all frequencies up to
beta. During previous EEG sleep studies, power in delta and theta
frequencies was increased by both drugs. The increases in low
frequency MEG power produced by gaboxadol and tiagabine were
associated with pronounced subjective effects particularly seda-
tion, and confusion with tiagabine [this is a major element in the
elevated SHAS score for this drug]. Early in our analyses, in fact on
inspection of raw data, we noticed that these there were highlysynchronous bursts of low frequency activity after the 2 drugs,
particularly tiagabine, took effect (see Fig. 6 and Supplementary
Materials for waveform examples from three individuals and also
Hamandi et al., 2014; Azar et al., 2013). This suggested that rela-
tively widespread cortical areas were being synchronised but
importantly it also directly impacts on the choice of methods used
to analyse the current data. It has been the approach not of only our
own group (Muthukumaraswamy et al., 2013a, 2013b; Saxena et al.,
2013) but also of others (Hall et al., 2010, 2011; Bauer et al., 2012;
Ronnqvist et al., 2013) to pharmaco-MEG data, to perform source
localisations, and this has been done primarily with beamformers
(Van Veen et al., 1997). While beamformers have excellent abilities
Fig. 7. Summary ﬁgure combining selected panels from Figs. 3e5. The time-points for each drugs showing the maximal effect has been selected (zolpidem ¼ 60 min,
gaboxadol ¼ 160 min, tiagabine ¼ 180 min).
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and environmental artefacts, they have the disadvantage that
highly correlated source activity can potentially be absent in
beamformer images. The best known example of such correlated
sources are the symmetrical sources that occur following auditory
stimulation and are difﬁcult to detect with beamfomer approaches
(Dalal et al., 2006; Brookes et al., 2007). It has been suggested that
there may well be relatively few distributed highly correlated
sources with regard to spontaneous activity (Hillebrand et al.,
2005), but this is less likely in the pathological or pharmacologi-
cally altered brain. As such, there is a need for a thorough quanti-
tative evaluation of MEG source localization techniques for these
types of data and would include not only beamformer approachesbut other common techniques such as the minimum norm ap-
proaches. Such an evaluation is beyond the scope of this work but
would be a valuable addition to the advancement of pharmaco-
MEG.
There are several limitations to the study that prevent a more
direct quantitative comparison of the different drugs being evalu-
ated. Speciﬁcally there is no way a priori to know the dose required
to generate a functional effect, and indeed all drugs evaluated here
have different pharmacodynamic time-courses. Each drug at mul-
tiple doses would need to be investigated to fully explore the
pharmacokineticepharmacodynamic relationship which was
beyond the scope of this study. The data for tiagabine was recorded
under slightly different experimental conditions (eyes-closed).
D. Nutt et al. / Neuropharmacology 88 (2015) 155e163162However, we attempted to reduce this as confound by ﬁrst sub-
tracting the pre-drug baseline spectra prior to comparing the active
dose with placebo to remove main effects of state (i.e. eyes open or
closed). As such any confounding differences would need to
confound the interaction effects (state  drug) rather than the
baseline power levels. Nevertheless Fig. 7 should be interpreted
qualitatively and with caution.
In conclusion this work shows that MEG is sensitive to the ac-
tions of three distinct types of positive GABA-Amodulators and that
there are distinctive differences in the patterns of MEG effects
produced. In particular the enhancement of tonic inhibition by via
extrasynaptic receptors by gaboxadol gives rise to a very different
MEG signature from that produced by the intrasynaptic PAM zol-
pidem. The GABA reuptake blocker tiagabine theoretically can lead
to effects on both types of receptor, the ﬁrst by blocking uptake in
the synapse and thus enhancing post-synaptic effects, and the
second by overspill of increased GABA to extrasynaptic areas. From
these MEG results it is likely that the latter is the more prominent
effect here, or at least this action obscures any intra-synaptic MEG
signal. Overall this research shows that MEG could play an impor-
tant role in determining the cortical effects of GABAergic medica-
tions and how their effects may relate to clinical efﬁcacy and
possibly unwanted actions. MEG could also be of use in exploring
the actions of new drugs designed to act at the GABA-A receptor.
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